预测晚期非小细胞肺癌铂类联合化疗疗效的变异体。
Variants of Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
机构信息
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
出版信息
Anticancer Res. 2020 Aug;40(8):4245-4251. doi: 10.21873/anticanres.14426.
BACKGROUND
Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives. SLC22A16 has functional genetic variants but the association between these variants and the effectiveness of antitumor drugs remains unexplored.
PATIENTS AND METHODS
This study retrospectively analyzed data from 160 patients with advanced non-small cell lung cancer treated with platinum-based combination chemotherapy for first-line chemotherapy between October 2010 and May 2018. We investigated the association between the genetic variant of SLC22A16 and clinical outcomes.
RESULTS
Patients with the rs714368 GG genotype had a shorter progression-free survival than those with AA or AG. Gene polymorphism was not associated with adverse effects. The predictive effect of rs714368 was confirmed in multivariate analysis using a Cox proportional hazards model.
CONCLUSION
A genetic variant of SLC22A16 is a potential predictive biomarker for response to platinum-based chemotherapy for non-small cell lung cancer.
背景
有机阳离子转运蛋白 6（OCT6）由溶质载体家族 22 成员 16（SLC22A16）编码，参与调节细胞对铂类衍生物的敏感性和耐药性。SLC22A16 具有功能性遗传变异，但这些变异与抗肿瘤药物疗效之间的关系尚未得到探索。
患者和方法
本研究回顾性分析了 2010 年 10 月至 2018 年 5 月期间接受铂类联合化疗作为一线化疗的 160 例晚期非小细胞肺癌患者的数据。我们研究了 SLC22A16 基因变异与临床结局之间的关系。
结果
与 AA 或 AG 基因型相比，携带 rs714368 GG 基因型的患者无进展生存期更短。基因多态性与不良反应无关。多因素 Cox 比例风险模型分析证实 rs714368 的预测作用。
结论
SLC22A16 的基因变异可能是预测非小细胞肺癌对铂类化疗反应的生物标志物。
Zotero 插件